F2RL1 and ischemia: In addition, since in experimental model the administration of a PAR2 antagonist has been described as a promising therapy for modulation of inflammatory processes, further studies are warrented to evaluate if the administration of a PAR2 antagonist could be beneficial also in equine patients for the prevention of inflammatory-mediated intestinal damage secondary to ischemia or ischemia-reperfusion injury.